内科理论与实践

内科理论与实践 >

2021 , Vol. 16 >Issue 04: 272 - 275

DOI: https://doi.org/10.16138/j.1673-6087.2021.04.011

综述

B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展

展开
  • 1.温州医科大学第二临床医学院,浙江 温州 325035
    2.上海交通大学附属第六人民医院血液科,上海 200233

收稿日期: 2021-03-10

  网络出版日期: 2022-07-25

收起

本文引用格式

常宇宸, 宋陆茜 . B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展[J]. 内科理论与实践, 2021 , 16(04) : 272 -275 . DOI: 10.16138/j.1673-6087.2021.04.011

参考文献

[1] Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis[J]. Mol Cell, 2001, 8(3): 705-711.
[2] Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences[J]. Mol Cell, 2016, 61(5): 695-704.
[3] Certo M, Del Gaizo Moore V, Nishimo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members[J]. Cancer Cell, 2006, 9(5): 351-365.
[4] Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia[J]. Cancer Cell, 2004, 6(3): 241-249.
[5] Reed JC. A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation?[J]. Leuk Res, 1996, 20(2): 109-111.
[6] Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia[J]. Blood, 2003, 101(2): 425-432.
[7] Fesik SW. Insights into programmed cell death through structural biology[J]. Cell, 2000, 103(2): 273-282.
[8] Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors[J]. Cell Death Differ, 2009, 16(7): 1030-1039.
[9] Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681.
[10] Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase Ⅰ study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30(5): 488-496.
[11] Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discov, 2014, 4(3): 362-375.
[12] Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase Ⅱ Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia[J]. Cancer Discov, 2016, 6(10): 1106-1117.
[13] Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells[J]. Ann Hematol, 2012, 91(12): 1861-1870.
[14] Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1[J]. Leukemia, 2018, 32(2): 303-312.
[15] Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia[J]. Nat Med, 2018, 24(12): 1859-1866.
[16] DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(2): 216-228.
[17] Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts[J]. Blood, 2015, 126(3): 291-299.
[18] Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-Dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ⅰb/Ⅱ study[J]. J Clin Oncol, 2019, 37(15): 1277-1284.
[19] DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. Engl J Med, 2020, 383(7): 617-629.
[20] Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial[J]. Blood, 2020, 135(24): 2137-2145.
Options
文章导航

/

〈 〉